Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Gene therapy has been developed as a potential novel treatment modality for colorectal cancer. The preclinical data have been promising and several clinical trials are under way for colorectal cancer. Data from many phase 1 trials have proven the safety of the reagents, but have not yet demonstrated significant therapeutic benefit. In order to refine this approach, continuing efforts should be made to improve the antitumour potency, efficiency of gene delivery, and accuracy of gene targeting. It is likely that gene therapy will be integrated into pre-existing therapies including surgery, chemotherapy and radiotherapy to establish its niche in tomorrow's medicine.

Original publication

DOI

10.1093/bmb/64.1.201

Type

Journal article

Journal

Br Med Bull

Publication Date

2002

Volume

64

Pages

201 - 225

Keywords

Clinical Trials, Phase I as Topic, Colorectal Neoplasms, Gene Transfer Techniques, Genes, p53, Genetic Therapy, Humans, Immunity, Cellular, T-Lymphocytes, Cytotoxic